Duodenal and cutaneous metastases from rectal cancer are rare and associated with poor prognosis. This case report describes a patient with advanced rectal cancer who developed these uncommon metastases after first-line therapy. Upon treatment with fruquintinib, the patient experienced a rapid and significant regression of the cutaneous lesions, demonstrating a visible clinical response. This suggests that fruquintinib may be an effective therapeutic option for patients with such aggressive and rare metastatic disease.
He et al. (Thu,) studied this question.